US Deregulation Efforts Undermined by Trump Administration's Anti-Science Agenda
The rapid development of mRNA vaccines during the Covid-19 pandemic has been hailed as a major scientific breakthrough, with scientists like Katalin Karikó and Drew Weissman winning the Nobel prize for their work. The technology uses synthetic genetic code to train the immune system to defend against viruses, and its versatility and speed have made it an attractive option for fighting other diseases such as flu, HIV, and even cancer.
However, the US Trump administration's rejection of mRNA vaccines is a significant setback, with the Department of Health and Human Services announcing a "coordinated wind-down" of federal funding for mRNA research. The decision to cancel $500m in funding for 22 projects will have devastating consequences, undermining public confidence and crippling the system meant to keep people safe.
The US's unpredictable regulatory environment has made it difficult for companies to invest in mRNA technology, with some firms now looking to develop personalised cancer vaccines that have escaped the Trump administration's notice. The pharmaceutical industry is keen to deliver and profit from mRNA technology, but an unstable US market makes this significantly more challenging.
In contrast, the UK and EU are stepping up to support mRNA research and development, with proposals for funding and investment in facilities. The European Commission has pledged €500m, while France has committed another €100m. With the forthcoming EU Biotech Act, Europe is well-positioned to surpass the US as the world's pre-eminent mRNA research and manufacturing centre.
As the global community comes together to support mRNA technology, it is clear that the US Trump administration's anti-science agenda has put its own interests ahead of public health. The world must now see this technology through, with the rest of the world playing a critical role in supporting research and development.
The rapid development of mRNA vaccines during the Covid-19 pandemic has been hailed as a major scientific breakthrough, with scientists like Katalin Karikó and Drew Weissman winning the Nobel prize for their work. The technology uses synthetic genetic code to train the immune system to defend against viruses, and its versatility and speed have made it an attractive option for fighting other diseases such as flu, HIV, and even cancer.
However, the US Trump administration's rejection of mRNA vaccines is a significant setback, with the Department of Health and Human Services announcing a "coordinated wind-down" of federal funding for mRNA research. The decision to cancel $500m in funding for 22 projects will have devastating consequences, undermining public confidence and crippling the system meant to keep people safe.
The US's unpredictable regulatory environment has made it difficult for companies to invest in mRNA technology, with some firms now looking to develop personalised cancer vaccines that have escaped the Trump administration's notice. The pharmaceutical industry is keen to deliver and profit from mRNA technology, but an unstable US market makes this significantly more challenging.
In contrast, the UK and EU are stepping up to support mRNA research and development, with proposals for funding and investment in facilities. The European Commission has pledged €500m, while France has committed another €100m. With the forthcoming EU Biotech Act, Europe is well-positioned to surpass the US as the world's pre-eminent mRNA research and manufacturing centre.
As the global community comes together to support mRNA technology, it is clear that the US Trump administration's anti-science agenda has put its own interests ahead of public health. The world must now see this technology through, with the rest of the world playing a critical role in supporting research and development.